NCT04917874 - A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions

Dystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis Bullosa

Interventions

BIOLOGICAL

Open Label Topical Beremagene Geperpavec (B-VEC)

Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein

Trial Locations (6)

33146

Pediatric Skin Research, Coral Gables

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Northwestern University, Chicago

78723

Ascension Seton- Dell's Children Medical Group, Austin

92688

Mission Dermatology Center, Rancho Santa Margarita

94063

Stanford University, Redwood City